Alison A McCormick
Overview
Explore the profile of Alison A McCormick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
486
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madapong A, Petro-Turnquist E, Webby R, McCormick A, Weaver E
Vaccines (Basel)
. 2024 Oct;
12(10).
PMID: 39460267
Background: The rapid production of influenza vaccines is crucial to meet increasing pandemic response demands. Here, we developed plant-made vaccines comprising centralized consensus influenza hemagglutinin (HA-con) proteins (H1 and H3...
2.
Zhou Y, McCormick A, Kearney C
Methods Mol Biol
. 2024 May;
2786:289-300.
PMID: 38814400
In this protocol, we outline how to produce a chimeric viral vaccine in a biosafety level 1 (BSL1) environment. An animal viral vector RNA encapsidated with tobacco mosaic virus (TMV)...
3.
Soo Hoo W, Higa K, McCormick A
Biology (Basel)
. 2023 Jul;
12(7).
PMID: 37508413
In this study, we demonstrate that expression of viral latent membrane protein 1 (LMP1) in a mouse B cell line renders the animals responsive to protection from a 38C13-LMP1 tumor...
4.
Royal J, Simpson C, McCormick A, Phillips A, Hume S, Morton J, et al.
Vaccines (Basel)
. 2021 Nov;
9(11).
PMID: 34835278
Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of the SARS-CoV-2 receptor-binding domain...
5.
DArco C, McCormick A, Arnaboldi P
Vaccine
. 2021 Feb;
39(9):1435-1444.
PMID: 33531196
Yersinia pestis, the causative agent of plague, has killed millions throughout human history. Though public health initiatives have reduced the number of plague cases, it remains endemic in many areas...
6.
Mansour A, Banik S, Suresh R, Kaur H, Malik M, McCormick A, et al.
Front Microbiol
. 2018 Jun;
9:1195.
PMID: 29922267
, the causative agent of the fatal human disease known as tularemia is classified as a Category A Select Agent by the Centers for Disease Control. No licensed vaccine is...
7.
McCormick A, Shakeel A, Yi C, Kaur H, Mansour A, Bakshi C
PLoS One
. 2018 Apr;
13(4):e0194614.
PMID: 29684046
Tularemia is a fatal human disease caused by Francisella tularensis, a Gram-negative encapsulated coccobacillus bacterium. Due to its low infectious dose, ease of aerosolized transmission, and lethal effects, the CDC...
8.
Zhou Y, McCormick A, Kearney C
Methods Mol Biol
. 2016 Dec;
1499:77-86.
PMID: 27987143
In this protocol, we outline how to produce a live viral nanoparticle vaccine in a biosafety level 1 (BSL1) environment. An animal viral vector RNA encapsidated with tobacco mosaic virus...
9.
Arnaboldi P, Sambir M, DArco C, Peters L, Seegers J, Mayer L, et al.
Vaccine
. 2016 Oct;
34(47):5768-5776.
PMID: 27745954
Yersinia pestis, one of history's deadliest pathogens, has killed millions over the course of human history. It has attributes that make it an ideal choice to produce mass casualties and...
10.
Banik S, Mansour A, Varadharajan Suresh R, Wykoff-Clary S, Malik M, McCormick A, et al.
PLoS One
. 2015 Jun;
10(6):e0130858.
PMID: 26098553
Francisella tularensis is a facultative intracellular pathogen, and is the causative agent of a fatal human disease known as tularemia. F. tularensis is classified as a Category A Biothreat agent...